Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229. Patients with advanced malignancies were eligible. There were two treatment cycles; ...

Leipzig and Berlin, Germany - In the setting of acute ST-elevation MI (STEMI) treated with PCI, giving the initial bolus of abciximab (ReoPro, Eli Lilly/Centocor) by the intracoronary (IC) route, ...

Asthma is an inflammatory disease typified by airway hyperreactivity and obstruction-producing airway resistance with a reduction in air flow. [1] The mainstay of treatment of acute asthma in children ...

ORLANDO, FL—Intracoronary abciximab does not reduce rates of death or myocardial infarction (MI) compared to standard intravenous (IV) administration of the glycoprotein IIb/IIIa inhibitor in patients ...

Interim safety summary of alemtuzumab vs. chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL) This is an ASCO Meeting Abstract from the 2004 ...

The VE response to I.V. bolus infusion of Dox is largely unkown, although Dox is used parenterally in the treatment of apnea of infancy. The objectives of this study were 1) to determine if VE ...

Paricalcitol 2mcg/mL, 5mcg/mL; soln for IV inj; contains alcohol. Give as IV bolus inj during dialysis. Initially 0.04–0.1mcg/kg (2.8–7mcg) no more often than every other day; may increase in ...

The glycoprotein IIb/IIIa inhibitor abciximab given as an intracoronary rather than intravenous (IV) bolus in patients undergoing primary percutaneous coronary intervention (PCI) may improve ...

At a recent meeting of the AAMI Healthcare Technology Safety Institute, researchers from the University of Toronto released a report that provides nine specific recommendations to reduce the risks ...

In the UK, four thrombolytic agents are licensed and available to treat AMI. All act by promoting the activity of circulating plasminogen. There is a long history of use of one, streptokinase, whereas ...